Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Brian Halbert"'
Autor:
David McDermott, Virginia Seery, Rupal Bhatt, Adrian Wells, Mamta Gupta, Brian Halbert, David Einstein, Emanuelle Andrianopoulos, Kenneth Onimus, Courtney Herman, Shwetha Lakshmipathi, Arvind Natarajan, Anand Veerapathran
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/ac294b04595448f389f6a445c691e5f3
Autor:
Rupal S. Bhatt, Venkata Sabbisetti, Robert S. DiPaola, Janice P. Dutcher, Robert G. Uzzo, Keith T. Flaherty, Naomi B. Haas, Brian Halbert, Mäneka Puligandla, Wenxin Xu
Distribution of baseline KIM-1 values
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c2cdee842352ce2986ce70fb8469fe7
https://doi.org/10.1158/1078-0432.22479431.v1
https://doi.org/10.1158/1078-0432.22479431.v1
Autor:
Rupal S. Bhatt, Venkata Sabbisetti, Robert S. DiPaola, Janice P. Dutcher, Robert G. Uzzo, Keith T. Flaherty, Naomi B. Haas, Brian Halbert, Mäneka Puligandla, Wenxin Xu
Purpose:No circulating biomarkers are currently available to identify patients at highest risk of recurrence after nephrectomy for renal cell carcinoma (RCC). Kidney injury molecule-1 (KIM-1) is overexpressed in RCC and its ectodomain circulates in p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::023abce43b4ba67ffd9261175ea90100
https://doi.org/10.1158/1078-0432.c.6530219.v1
https://doi.org/10.1158/1078-0432.c.6530219.v1
Autor:
Rupal S. Bhatt, Venkata Sabbisetti, Robert S. DiPaola, Janice P. Dutcher, Robert G. Uzzo, Keith T. Flaherty, Naomi B. Haas, Brian Halbert, Mäneka Puligandla, Wenxin Xu
Sensitivity analysis AFT model for DFS with imputation of KIM-1 levels below lower limit of detection (9.1 pg/mL)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60968f0a12d57003b66de2cf3e4dce11
https://doi.org/10.1158/1078-0432.22479410
https://doi.org/10.1158/1078-0432.22479410
Autor:
Brian Halbert, David J. Einstein
Publikováno v:
Urology. 147:119-126
Pembrolizumab was recently approved for treatment of cancers with high tumor mutational burden (TMB). We conduct a focused literature review of TMB as a predictive biomarker. TMB quantifies the sum of nonsynonymous coding mutations (typically single
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2020f5abb57622956212dab3a0855131
https://doi.org/10.1016/j.urology.2020.10.030
https://doi.org/10.1016/j.urology.2020.10.030
Autor:
Keith T. Flaherty, Maneka Puligandla, Naomi B. Haas, Wenxin Xu, Rupal S. Bhatt, Robert G. Uzzo, Venkata S. Sabbisetti, Brian Halbert, Janice P. Dutcher, Robert S. DiPaola
Publikováno v:
Clin Cancer Res
Purpose: No circulating biomarkers are currently available to identify patients at highest risk of recurrence after nephrectomy for renal cell carcinoma (RCC). Kidney injury molecule-1 (KIM-1) is overexpressed in RCC and its ectodomain circulates in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec2dc29f162d14fe5cdfa483901cf5ec
https://pubmed.ncbi.nlm.nih.gov/33832947
https://pubmed.ncbi.nlm.nih.gov/33832947
Publikováno v:
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 29(7)
Oncology patients disproportionately utilize the emergency department (ED) for symptom management. At our institution, approximately 1 in 4 visits to the ED by oncology patients led to discharge. We hypothesized that many of the visits leading to ED
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9cf05f331aeeb3f3fe2b663413d503c
https://pubmed.ncbi.nlm.nih.gov/33159604
https://pubmed.ncbi.nlm.nih.gov/33159604
Publikováno v:
JTO Clinical and Research Reports
JTO Clinical and Research Reports, Vol 1, Iss 4, Pp 100071-(2020)
JTO Clinical and Research Reports, Vol 1, Iss 4, Pp 100071-(2020)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5267422027d42dab26b6dad597d6ec14
http://europepmc.org/articles/PMC7305494
http://europepmc.org/articles/PMC7305494
Autor:
Brian Halbert, David Einstein, David McDermott, Emanuelle Andrianopoulos, Mamta Gupta, Virginia Seery, Kenneth Onimus, Courtney Herman, Adrian Wells, Shwetha Lakshmipathi, Arvind Natarajan, Anand Veerapathran, Rupal Bhatt
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundPatients with RCC may achieve remission with immune-checkpoint inhibitors (ICI); however, most patients will progress. Adoptive cell therapy with autologous TIL allows for expansion of T-cells from tumor tissue leading to a polyclonal T-cel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b0f7e44e3bde4ea1e72ec0df4f22c31
https://doi.org/10.1136/jitc-2021-sitc2021.176
https://doi.org/10.1136/jitc-2021-sitc2021.176
Autor:
Robert G. Uzzo, Naomi B. Haas, Wenxin Xu, Maneka Puligandla, Keith T. Flaherty, Venkata S. Sabbisetti, Janice P. Dutcher, Rupal S. Bhatt, Brian Halbert, Robert S. DiPaola
Publikováno v:
Journal of Clinical Oncology. 39:342-342
342 Background: Recurrence is common after nephrectomy for renal cell carcinoma (RCC), but no circulating biomarkers are available to identify patients at highest risk of recurrence who may benefit from adjuvant therapy. Kidney injury molecule-1 (KIM
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::81c0eda876fc881dd30d2c1c6c931320
https://doi.org/10.1200/jco.2021.39.6_suppl.342
https://doi.org/10.1200/jco.2021.39.6_suppl.342